79
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Biochemical and clinical impacts of miR-150 and miR-21 expression levels in diffuse large B cell lymphoma

, , , , &

References

  • Lopez-Santillan, M.; Larrabeiti-Etxebarria, A.; Arzuaga-Mendez, J.; Lopez-Lopez, E.; Garcia-Orad, A. Circulating miRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Systematic Review. Oncotarget. 2018, 9(32), 22850–22861. DOI: 10.18632/oncotarget.25230.
  • Ruppert, A. S.; Dixon, J. G.; Salles, G.; Wall, A.; Cunningham, D.; Poeschel, V.; Haioun, C.; Tilly, H.; Ghesquieres, H.; Ziepert, M., et al. International Prognostic Indices in Diffuse Large B-cell Lymphoma: A Comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020, 135(23), 2041–2048.
  • Pfeffer, S. R.; Yang, C. H.; Pfeffer, L. M. The Role of miR-21 in Cancer. Drug Dev. Res. 2015, 76(6), 270–277. DOI: 10.1002/ddr.21257.
  • Yáñez-Mó, M.; Siljander, P. R.; Andreu, Z.; Zavec, A. B.; Borràs, F. E.; Buzas, E. I.; Buzas, K.; Casal, E.; Cappello, F.; Carvalho, J., et al. Biological Properties of Extracellular Vesicles and Their Physiological Functions. J Extracell Vesicles. 2015, 14, 27004–27066.
  • He, Y.; Jiang, X.; Chen, J. The Role of miR-150 in Normal and Malignant Hematopoiesis. Oncogene. 2014, 33(30), 3887–3893. DOI: 10.1038/onc.2013.346.
  • Selcuklu, S. D.; Donoghue, M. T.; Spillane, C. miR-21 as a Key Regulator of Oncogenic Processes. Biochem. Soc. Trans. 2009, 37, 918–925. DOI: 10.1042/BST0370918.
  • Liu, K.; Du, J.; Ruan, L. MicroRNA-21 Regulates the Viability and Apoptosis of Diffuse Large B-cell Lymphoma Cells by Upregulating B Cell Lymphoma-2. Exp. Ther. Med. 2017, 14(5), 4489–4496. DOI: 10.3892/etm.2017.5021.
  • Buscaglia, L. E.; Li, Y. Apoptosis and the Target Genes of microRNA-21. Chin J Cancer. 2011, 30(6), 371–380. DOI: 10.5732/cjc.30.0371.
  • Foussard, C.; Desablens, B.; Sensebe, L.; François, S.; Milpied, N.; Deconinck, E.; Delwail, V.; Dugay, J.; Lamy, T.; Ghandour, C., et al. Is the International Prognostic Index for Aggressive Lymphomas Useful for low-grade Lymphoma Patients? Applicability to Stage III-IV Patients. The GOELAMS Group, France. Ann. Oncol. 1997, 8, 49–52. DOI: 10.1093/annonc/8.suppl_1.S49.
  • Witt, D. C.; Trendelenburg, C. Joint Study to Establish Reference Values for Clinical Chemical Parameters. J. Clin. Chem. Clin. Biochem. 1982, 20(4), 235.
  • Gilmour, D.; Sykes, A. J. Westergren and Wintrobe Methods of Estimating E.S.R. Compared. Br. Med. J. 1951, 2(4746), 1496–1497. DOI: 10.1136/bmj.2.4746.1496.
  • Grützner, F. J. Diagnostics Mit. β2-Microglobulin. Inn Med. 1982, 9, 45.
  • Henderson, A. R.; Moss, D. W. Enzymes, Tietz Fundamentals of Clinical Chemistry 5th Burtis, C. A., Ashwood, E. R. Philadelphia USA: W.B. Saunders;2001. 352.
  • Henry, R. J. Clinical Chemistry. Principals and Technics; 2nd; New York: Hoeber Medical Division, Harper and Row, 1974; pp 525.
  • Rao, X.; Huang, X.; Zhou, Z.; Lin, X. An Improvement of the 2 (Delta Delta CT) Method for Quantitative real-time Polymerase Chain Reaction Data Analysis. Biostat Bioinforma Biomath 2013, 3(3), 71–85.
  • El-Senbawy, M. S.; Abd El Bary, N. M.; Shehata, M. A. Cancer Statistics in Menoufia University Hospital 2012–2013: A Trial of Cancer Registry in Menoufia University Hospital. Menoufia Med. J. 2018, 16(12), 582–587.
  • Quesada, A. E.; Medeiros, L. J.; Desai, P. A. Increased MYC Copy Number Is an Independent Prognostic Factor in Patients with Diffuse Large B-cell Lymphoma. Mod. Pathol. 2017, 30, 1688. DOI: 10.1038/modpathol.2017.93.
  • Pasqualucci, L., and Ott, G. Pathology and Molecular Pathogenesis of DLBCL and Related Entities. In Aggressive Lymphomas, Part of the Hematologic Malignancies Book Series; Lenz, G., Lenz, G.; 2019, 41-73. DOI: 10.1007/978-3-030-00362-3_2.
  • Vasilatou, D.; Papageorgiou, S.; Pappa, V.; Papageorgiou, E.; Dervenoulas, J. The Role of microRNAs in Normal and Malignant Hematopoiesis. Eur. J. Haematol. 2010, 84(1), 1–16. DOI: 10.1111/j.1600-0609.2009.01348.x.
  • Song, J.; Shao, Q.; Li, C.; Liu, H.; Li, J.; Wang, Y.; Song, W.; Li, L.; Wang, G.; Shao, Z., et al. Effects of microRNA-21 on Apoptosis by Regulating the Expression of PTEN in Diffuse Large B-cell Lymphoma. Medicine. 2017, 96(39), e7952.
  • Sultan, S.; Baloch, N.; Ahmed, Z. A.; Irfan, S. M.; Parveen, S. Pattern of Bone Marrow Involvement in Non Hodgkin’s Lymphoma Classified according to WHO Classification. J. Lab. Phys. 2018, 10(1), 17–20.
  • Abdelhamid, T.; Samra, M.; Ramadan, H. Clinical Prognostic Factors of Diffuse Large B Cell nonHodgkin Lymphoma: A Retrospective Study. J. Egyp. Nat. Cancer Institute. 2011, 23(1), 17–24. DOI: 10.1016/j.jnci.2011.07.003.
  • Conlan, M. G.;.; Armitage, J. O.;.; Bast, M.; Weisenburger, D. D. Clinical Significance of Hematologic Parameters in non-Hodgkin’s Lymphoma at Diagnosis. Cancer. 1991, 67(5), 1389–1395. DOI: 10.1002/1097-0142(19910301)67:5<1389::AID-CNCR2820670519>3.0.CO;2-Q.
  • Oana, M. C.; Elena, M. L.; Emoke, H.; Horea, G.; Ioana, C. M. Non-Hodgkin Lymphoma, Diagnostic and Prognostic. Medicine. 2018, 97(8), 9802.
  • Jiang, T.; Ding, X.; Lu, W. The Prognostic Significance of Beta 2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis. Dis. Markers. 2016, 10, 959.
  • Galleze, A.; Raache, R.; Cherif, N.; Eddaïkra, A.; Belhani, M.; Bensenouci, A.; Touil-Boukoffa, C.; Abbadi, M. C.; Attal, N. Increased Level of Lactate Dehydrogenase Correlates with Disease Growth in Children with Lymphoma. J. Hematol. Oncol. 2016, 2(4), 80–83.
  • Caramuta, S.; Lee, L.; Özata, D. M.; Akçakaya, P.; Georgii-Hemming, P.; Xie, H.; Amini, R. M.; Lawrie, C. H.; Enblad, G.; Larsson, C., et al. Role of microRNAs and microRNA Machinery in the Pathogenesis of Diffuse Large B-cell Lymphoma. Blood Cancer J. 2013, 3(10), 152. DOI: 10.1038/bcj.2013.49
  • Lawrie, C. H.; Chi, J.; Taylor, S.; Tramonti, D.; Ballabio, E.; Palazzo, S.; Saunders, N.; Pezzella, F.; Boultwood, J.; Wainscoat, J., et al. Expression of microRNAs in Diffuse Large B Cell Lymphoma Is Associated with Immunophenotype, Survival and Transformation from Follicular Lymphoma. J. Cell Mol. Med. 2009, 13(7), 1248–1260.
  • Szurián, K.; Csala, I.; Piurkó, V.; Deák, L.; Matolcsy, A.; Reiniger, L. Quantitative miR Analysis in Chronic Lymphocytic leukaemia/small Lymphocytic Lymphoma - Proliferation Centres are Characterized by High miR-92a and miR-155 and Low miR-150 Expression. Leuk. Res. 2017, 58, 39–42. DOI: 10.1016/j.leukres.2017.04.002.
  • Fayyad-Kazan, H.; Bitar, N.; Najar, M.; Lewalle, P.; Fayyad-Kazan, M.; Badran, R.; Hamade, E.; Daher, A.; Hussein, N.; ElDirani, R., et al. Circulating miR-150 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia. J. Transl. Med. 2013, 7, 11–31.
  • Ito, M.; Teshima, K.; Ikeda, S.; Kitadate, A.; Watanabe, A.; Nara, M.; Yamashita, J.; Ohshima, K.; Sawada, K.; Tagawa, H. MicroRNA-150 Inhibits Tumor Invasion and Metastasis by Targeting the Chemokine Receptor CCR6, in Advanced Cutaneous T-cell Lymphoma. Blood. 2014, 123(10), 1499–1511. DOI: 10.1182/blood-2013-09-527739.
  • Watanabe, A.; Tagawa, H.; Yamashita, J.; Teshima, K.; Nara, M.; Iwamoto, K.; Kume, M.; Kameoka, Y.; Takahashi, N.; Nakagawa, T., et al. The Role of microRNA-150 as a Tumor Suppressor in Malignant Lymphoma. Leukemia. 2011, 25(8), 1324–1334.
  • Chen, J.; Xu, T.; Chen, C. The Critical Roles of miR-21 in anti-cancer Effects of Curcumin. Ann. of Transl. Med. 2015, 3–21. doi:10.3978/j.2305-5839.2014.12.10.
  • Uma Maheswari, T. N.; Nivedhitha, M. S.; Ramani, P. Expression Profile of Salivary Micro RNA-21 and 31 in Oral Potentially Malignant Disorders. Braz. Oral. Res. 2020, 10–34.
  • Wang, X.; Kan, Y.; Chen, L.; Ge, P.; Ding, T.; Zhai, Q.; Yu, Y.; Wang, X.; Zhao, Z.; Yang, H., et al. miR-150 Is a Negative Independent Prognostic Biomarker for Primary Gastrointestinal Diffuse Large B-cell Lymphoma. Oncol. Lett. 2020, 19(5), 3487–3494.
  • Guo, X.; Lv, X.; Lv, X.; Ma, Y.; Chen, L.; Chen, Y. Circulating miR-21 Serves as a Serum Biomarker for Hepatocellular Carcinoma and Correlated with Distant Metastasis. Oncotarget. 2017, 8(27), 44050–44058. DOI: 10.18632/oncotarget.17211.
  • Rudresha, A.; Asati, V.; Kuntegowdanahalli, L.; Babu, G.; Lokanatha, D.; Jacob, L. A.; Babu, S.; Premalatha, C. S.; Rajeev, L.; Lokesh, K. N., et al. Role of Prophase Treatment in Indian DLBCL Patients. Ann. Oncol. 2017, 28(5), 355–377.
  • Yildirim, R.; Sincan, G. The Clinicopathologic Features and Response to Treatment of Patients with Nonhodgkin Lymphoma: A Single Center Experiment in Turkey. Pak. J. Med. Sci. 2019, 35(1), 82–85. DOI: 10.12669/pjms.35.1.415.
  • Shenoy, P. J.; Malik, N.; Nooka, A.; Sinha, R.; Ward, K. C.; Brawley, O. W.; Flowers, C. R. Racial Differences in the Presentation and Outcomes of Diffuse Large B‐cell Lymphoma in the United States. Cancer. 2011, 117(11), 2530–2540. DOI: 10.1002/cncr.25765.
  • Roschewski, M.; Staudt, L. M.; Wilson, W. H. Diffuse Large B-cell lymphoma—treatment Approaches in the Molecular Era. Nat. Rev. Clin. Oncol. 2014, 11(1), 1–12. DOI: 10.1038/nrclinonc.2013.197.
  • AlShemmari, S. H.; Ameen, R. M.; Sajnani, K. P. Extranodal Lymphoma: A Comparative Study. Hematology. 2008, 13(3), 163–169. DOI: 10.1179/102453308X316149.
  • Møller, M.; Pedersen, N. T.; Christensen, B. E. Diffuse Large B‐cell Lymphoma: Clinical Implications of Extranodal versus Nodal presentation–a Population‐based Study of 1575 Cases. Br. J. Haematol. 2004, 124(2), 151–159. DOI: 10.1046/j.1365-2141.2003.04749.x.
  • Horvat, M.; Zadnik, V.; Šetina, T. J.; Boltežar, L.; Goličnik, J. A.; Novaković, S.; Novaković, B. J. Diffuse Large B-cell Lymphoma: 10 Years’ real-world Clinical Experience with Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone. Oncol. Letters. 2018, 15, 3602–3609.
  • Advani, R. H.; Habermann, T. M.; Morrison, V. A.; Weller, E. A.; Fisher, R. I.; Peterson, B. A.; Gascoyne, R. D.; Horning, S. J. Comparison of Conventional Prognostic Indices in Patients Older than 60 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): Consideration of Age Greater than 70 Years in an Elderly Prognostic Index (E-IPI). Br. J. Haematol. 2010, 151(2), 143–151. DOI: 10.1111/j.1365-2141.2010.08331.x.
  • Zhang, W.; Chen, J.; He, G.; Xu, W.; He, G. Impact of miRNA-21 on Survival Prognosis in Patients with Pancreatic Cancer: A Protocol for Systematic Review and meta-analysis. Medicine. 2020, 99(35), e22045. DOI: 10.1097/MD.0000000000022045.
  • Zhou, X.; Wang, X.; Huang, Z.; Wang, J.; Zhu, W.; Shu, Y.; Liu, P. Prognostic Value of miR-21 in Various Cancers: An Updating meta-analysis. PLoS One. 2014, 9(7), e102413. DOI: 10.1371/journal.pone.0102413.
  • Maminezhad, H.; Ghanadian, S.; Pakravan, K.; Razmara, E.; Rouhollah, F.; Mossahebi-Mohammadi, M.; Babashah, S. A Panel of Six Circulating miRNA Signature in Serum and Its Potential Diagnostic Value in Colorectal Cancer. Life Sci. 2020, 258, 118226. DOI: 10.1016/j.lfs.2020.118226.
  • Asker, H. A.; Khorshed, E. N.; Ahmed, M. R.; Refaat, L. A.; Khaled, H. M.; Rashed, R. A. 2021. Prognostic Values of Micro RNA-21 and Ki-67 in Diffuse Large B-Cell Lymphoma Patients, Egyptian Experience. Clin. Lab 67(7) DOI: 10.7754/Clin.Lab.2021.201132.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.